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Adjuvant chemotherapy and radiation 
therapy with the “sandwich” method 
for endometrial cancer: an institutional 
analysis
ABSTRACT 
Introduction. Choice of adjuvant therapy for high risk endometrial cancers is controversial. The so-called “sand-
wich” regimen of pelvic external beam radiation administered between cycles of Carboplatin/Paclitaxel (CT-RT-CT) 
is commonly used in clinical practice but has not been evaluated in randomized endometrial cancer trials. There 
is relatively little published data regarding toxicity, patient tolerance, and efficacy of this regimen. Here, we report 
our institutional experience of CT-RT-CT for locally advanced endometrial cancer, focusing on toxicity and rates 
of compliance with study therapy.
Material and methods. Medical records of consecutive patients treated for surgically staged endometrial cancer 
at a tertiary care academic medical center between 2010 and 2017 were reviewed. All patients received adjuvant 
CT-RT-CT. Progression-free and overall survival were recorded from the date of surgery. Toxicity data was obtained 
from patient medical records and graded according to Common Terminology for Adverse Events Criteria, version 3.0.
Results. Thirty-eight patients with histologically proven stage I–IV endometrial cancer were included. Eighty-four 
percent of patients were able to complete all 6 planned cycles of chemotherapy and 92% completed at least 
4 cycles. Cumulative incidence of grade 3–4 hematologic toxicity was 55%. Locoregional recurrence was the first 
site of failure in 2 patients (5.1%) while distant failure was the first site of recurrence in 8 patients (21%). Two year 
overall survival and progression-free survival were 76% and 77% respectively.
Conclusion. Our results suggest that adjuvant chemotherapy and radiation therapy with the “sandwich” regimen 
is associated with acceptable toxicity and satisfactory rates of completion of planned therapy.
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Endometrial cancer is the most common gyneco-
logic cancer in the United States, with an estimated 
63,230 cases and 11,350 deaths annually [1]. Standard 
therapy includes surgical staging followed by adjuvant 
chemotherapy and/or radiation therapy in patients 
with high-risk clinical or pathologic characteristics 
[2, 3]. For patients with advanced-stage endometrial 
cancer, the choice of adjuvant therapy remains con-
troversial. 
Several early phase clinical trials and single insti-
tution clinical series have demonstrated the efficacy 
of adjuvant radiation or chemotherapy used as single 
modality treatments. Studies of adjuvant chemotherapy 
alone show high rates of local disease recurrence in the 
pelvis compared to trials in which radiation is given. 
Conversely, patients treated with radiation alone show 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to 
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higher rates of distant failure. These observations were 
confirmed in GOG 122, a multi-institutional randomized 
clinical trial directly comparing chemotherapy versus 
whole abdominal radiation [4]. 
To optimize both distant and local control, combi-
nation chemotherapy and radiation therapy regimens 
are often favored in current practice and are endorsed 
in published treatment guidelines from the American 
Society for Radiation Oncology (ASTRO), and in 
a joint statement by the Society of Obstetrics and 
Gynecologists of Canada/Society of Gynecologic On-
cology of Canada/Society of Canadian Colposcopists 
[3, 5]. However, there is significant institutional and 
provider variation in the specific adjuvant regimens 
used, with commonly employed regimens based 
primarily on results from early phase studies or ret-
rospective reviews of institutional experiences [6–8]. 
Published data from randomized clinical trials provid-
ing direct comparisons between combination regimens 
are limited.
Results of two recently completed randomized trials 
(GOG 258 and PORTEC 3) provide important insights 
into the relative benefits of various adjuvant regimens 
[9, 10]. In these trials, patients were randomized to 
a regimen of concurrent cisplatin based chemotherapy 
and pelvic radiation followed by 4 cycles of adjuvant 
carboplatin and paclitaxel (C-RT) versus a regimen 
of six cycles of carboplatin and paclitaxel alone (CT) 
in GOG 258 or pelvic external beam radiation alone 
(RT) in PORTEC 3. Published results of these trials 
confirmed a relative local control benefit with C-RT 
relative to CT, a distant control benefit to CT relative 
to C-RT. In PORTEC 3, an overall survival benefit was 
demonstrated with C-RT compared to RT alone [9–11]. 
However, C-RT was associated with increased toxicity 
and decreased rates of compliance with the 4 cycles 
of adjuvant carboplatin/paclitaxel. Survival analysis is 
pending for GOG 258. 
A third treatment regimen, commonly referred to as 
“sandwich” therapy, is often used in clinical practice and 
consists of pelvic external beam radiation administered 
between the 3rd and 4th cycles of a six-cycle regimen of 
carboplatin and paclitaxel chemotherapy [12]. Sandwich 
chemotherapy and radiation (CT-RT-CT) has the po-
tential advantage of providing the local control benefit 
associated with pelvic radiation as well as the distant 
control associated with the completion of 6 cycles of 
carboplatin/paclitaxel chemotherapy. However, this 
regimen has never been evaluated in a randomized trial 
and published literature regarding efficacy and toxicity 
is relatively sparse. Additional clinical data regarding 
this regimen is needed. Here, we report our institutional 
experience with CT-RT-CT for endometrial cancer, 
focusing on treatment efficacy, toxicity, and rates of 
compliance with planned therapy.
Material and methods 
Patient selection
Following IRB approval, we retrospectively identi-
fied patients treated at a single, tertiary care academic 
medical center who were diagnosed and treated for 
FIGO 2009 stage IA–IVB high risk endometrial cancer. 
High risk features included cervical stromal invasion, 
serosal/adnexal involvement, vaginal/parametrial in-
volvement, bladder/rectal involvement, nodal involve-
ment, and non-endometrioid histology. All patients were 
treated with hysterectomy and adjuvant CT-RT-CT 
between June 2011 and May 2017. Only patients treated 
with three cycles of carboplatin and paclitaxel followed 
by pelvic radiation and then additional cycles of chemo-
therapy were included. Patients who received concurrent 
chemotherapy with radiation were excluded, as were 
any patients treated with neoadjuvant chemotherapy.
Patient and tumor characteristic
Patient tumor and treatment characteristics were 
obtained from the electronic medical record. Variables 
recorded include age, race, tobacco, T stage, N stage, 
FIGO stage, surgical technique, pathologic findings, 
chemotherapy characteristics, radiation characteris-
tics, hematologic toxicity, and recurrence. Length of 
follow-up was calculated from the date of surgery and 
the date of the most recent follow-up documented in the 
medical record. Progression-free and overall survival 
were recorded from the date of surgery. Toxicity was 
graded according to Common Terminology for Adverse 
Events Criteria, version 3.0.
Statistical analysis
Univariate and multivariable logistic regression 
models were used to test for associations between 
patient characteristics and clinical outcomes. P val-
ues < 0.05 were considered significant. All statistical 




We identified a total of 38 patients who met the 
inclusion criteria. Median age was 65 years and ranged 
from 38–88 years (Tab. 1). Eighty-three percent of 
patients were Caucasian. Forty-two percent of patients 
had a history of tobacco use. Bilateral pelvic lymph 
node dissection was performed in 90% of patients 
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Table 1. Patient and cancer characteristics (n = 38)
Characteristic n (%)
Age at surgery (median, years) 65 (range 38–88)
Race
     Caucasian 31 (82%)
     African American 4 (11%)
     Other 3 (8%)
Tobacco use
     Yes 16 (42%)
     No 22 (58%)
Histology
     Endometrioid 18 (48%)
     Clear cell 0
     Serous 9 (25%)
     Mixed/Undifferentiated/Other 11 (28%)
Tumor grade
     1 3 (8%)
     2 10 (26%)
     3 25 (66%)
AJCC stage
     IA 2 (5%)
     IB 0
     II 5 (13%)
     IIIA 5 (13%)
     IIIC1 14 (37%)
     IIIC2 9 (24%)
     IVA 1 (3%)
     IVB 2 (5%)
Table 2. Treatment characteristics
Characteristic N (%)
Chemotherapy — number of cycles 
completed
     3 3 (8%)
     4 1 (2.7%)
     5 2 (5%)
     6 32 (84%)
External beam radiation dose (median, Gy)* 45 (range 45–55.8)
     45 Gy 34 (92%)
     50.4 Gy 2 (5%)
     55.8 Gy 1 (2.7%)
Radiation technique*
     3D 12 (32%)
     IMRT 25 (68%)
Radiation field*
     Pelvic 24 (65%)
     Pelvic + para-aortic 13 (35%)
Brachytherapy
     Yes 24 (65%)
          Brachytherapy dose (median, Gy) 18 (range 10–18)
     No 13 (35%)
*Radiation records for one patient was not available
and para-aortic dissection was performed in 65% of 
patients. The majority of patients (74%) had stage III 
disease and 8% of patients had stage IV disease. 
Chemotherapy 
Six cycles of chemotherapy were planned for each 
patient. All patients completed the 3 cycles of chemo-
therapy delivered before radiation therapy. Eighty-four 
percent of patients were able to complete all 6 planned 
cycles of chemotherapy and 92% of patients were able 
to complete at least 4 cycles (Tab. 2). Seventy-five per-
cent of patients received Pegfilgrastim. Chemotherapy 
was not completed due to neuropathy for two patients, 
thrombocytopenia for one patient, progression of 
disease for one patient, personal decision in one case, 
and unknown in one case. Seventy-three percent ex-
perienced no toxicity related delays in administration 
of chemotherapy during their treatment course. There 
were 11 patients whose chemotherapy treatments were 
delayed: 5 for thrombocytopenia, 1 for pancytopenia, 
3 for neutropenia, 1 for an unrelated hospitalization, 
and 1 for influenza.
Radiation therapy
The majority of patients received 45 Gy of external 
beam radiation (EBRT) (range 45–55.8 Gy). All patients 
completed their planned external beam radiation treat-
ment course. Sixty-eight percent of patients received 
intensity-modulated radiation therapy (IMRT) while 
32% received 3-dimensional conformal radiation therapy 
(3D CRT). High dose rate vaginal brachytherapy was used 
in 65% of cases, with a median dose of 18Gy in 3 fractions.
Toxicity
Over the course of chemotherapy and radiation 
therapy, grade 3 anemia was experienced by 21% of 
patients and grade 4 anemia by 3% of patients (Tab. 3). 
Grade 3 and 4 thrombocytopenia were each experi-
enced by 8% of patients. Twenty-six percent of patients 
developed grade 3 leukopenia and 13% of patients de-
veloped grade 4 leukopenia. Grade 3 and 4 neutropenia 
were each experienced by 24% of patients. The overall 
cumulative incidence of grade 3–4 hematologic toxicity 
was 55%. There were no grade 5 hematologic toxicities.
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Table 3. Hematologic toxicity during chemotherapy and radiation therapy
Grade Anemia Thrombocytopenia Leukopenia Neutropenia
0 1 (3%) 5 (13%) 4 (11%) 9 (24%)
1 7 (18%) 21 (55%) 7 (18%) 7 (18%)
2 21 (55%) 6 (16%) 12 (32%) 4 (11%)
3 8 (21%) 3 (8%) 10 (26%) 9 (24%)
4 1 (3%) 3 (8%) 5 (13%) 9 (24%)
Table 4. Characteristics of patients with recurrences
Age at 
surgery












56 IIIC2 6 45 18 Yes 15 Mediastinum
65 IIIC2 6 45 18 Yes 39 Peritoneal cavity/Liver
71 IIIC2 3 45 10 Yes 38 Peritoneal cavity
72 IIIC1 6 45 0 No 13 Vaginal cuff
73 IVB 6 45 18 No 16 Pulmonary and pelvic
73 IIIC2 6 45 0 Yes 2.5 Pulmonary
73 IIIC2 4 45 10 Yes 6.2 Peritoneal cavity
75 II 6 Not 
available
Not available Not available 7.8 Pulmonary
79 IVB 6 45 0 Yes 9.6 Vaginal cuff
81 IIIA 5 45 18 Yes 12 Liver
Treatment outcomes
Median follow up in our patient population was 
24 months. The 2-year overall survival was 76.4% and 
the 2-year progression free survival (Fig. 1) was 76.6%. 
Time to progression ranged from 6 to 39 months (me-
dian 12 months). Distant metastasis was the first site of 
failure in 8 patients (21%), while locoregional recur-
rence was the first site of failure in 2 patients (5.1%). 
Characteristics of patients who experienced recurrences 
are provided in Table 4. Both patients with locoregional 
recurrence presented with vaginal disease recurrence as 
the first site of failure.
On univariate analysis, the only predictor for im-
proved overall survival was the completion of planned 
chemotherapy (HR 4.3; 95% CI 1.03–18.3). Kaplan 
Meier analysis of overall survival, stratified by whether 
or not patients completed all planned cycles of chemo-
therapy, is shown in Figure 2. The only significant 
predictor for improved progression-free survival was 
lower age (HR 1.03, 95% CI 1.0–1.2), which was cal-
culated as a continuous variable. Distant metastasis 
free survival was significantly improved among patients 
who completed all planned cycles of chemotherapy 
(HR 6.3; 95% CI 1.5–27.5) and amongst patients who 
had no delayed or missed cycles of chemotherapy 
(HR 2.4; 95% CI > 1.0–5.7).
Discussion
We report our institutional experience treating pa-
tients with high risk endometrial cancer using adjuvant Figure 1. Kaplan-Meier analysis for progression-free survival
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“sandwich” therapy with pelvic external beam radia-
tion administered between cycles 3 and 4 of a planned 
6 cycles of carboplatin/paclitaxel chemotherapy. Our 
results show this regimen is associated with high rates of 
compliance with planned therapy, with 92% of patients 
completing at least 4 cycles of carboplatin/paclitaxel 
chemotherapy and 100% completing planned radia-
tion treatments. In addition, we found low rates of lo-
coregional failure (5%) and distant metastases (21%). 
Lower age was found to be a significant predictor for 
improved progression-free survival. This is in line with 
current literature reports of older age as a risk factor 
for recurrence and poor outcomes [13, 14]. 
Given the limited published clinical data regard-
ing sandwich therapy, our findings provide important 
additional information regarding efficacy and toxicity 
of this regimen in a patient population that closely 
resembles results from recent randomized trials (GOG 
258 and PORTEC 3) using combination adjuvant 
therapy regimens with radiation and chemotherapy. 
Our results show similar rates of locoregional disease 
control relative to other series of sandwich therapy, 
with reported rates or locoregional failure ranging 
from 2–15% in a recently published meta-analysis 
[12]. Our findings are also in line with the 5-year 
overall survival of 70% and 5-year progression free 
survival of 66% reported for stage III, IV and recur-
rent endometrial cancer patients treated with sandwich 
therapy in a recently published long term follow-up of 
a phase II study [15]. Our patient population did have 
a large proportion (25%) of serous histology. A study 
of 81 patients with uterine papillary serous carcinoma 
treated with the sandwich regimen found overall pro-
gression free survival and overall survival of 65.5% and 
76.5% in early-stage patients and 25.8% and 35.9% in 
advanced stage patients [16]. These numbers compare 
similarly with our 2-year overall survival of 76.4% and 
the 2-year progression free survival of 76.6% for our 
entire patient population. 
Our findings also compare favourably with patients 
treated with radiation in both PORTEC 3 and GOG 
258. In PORTEC 3, 5-year rates of pelvic or vaginal re-
currence as the first site of failure among patients treated 
with C-RT and RT were 1.3% and 1.8%, respectively 
[10]. In GOG 258, the incidence of vaginal recurrence 
was 2% at 5 years, and locoregional recurrence 11% 
at 5 years among patients treated with pelvic radiation 
on the C-RT treatment arm [9]. The patients in GOG 
258 did have higher risk disease with 97.3% having 
stage III or higher disease as compared to patients in 
PORTEC 3 in which only 43% of patients had stage III 
disease (there were no patients with stage IV disease). 
The patients in our study had more similar disease se-
verity to the patients in GOG 258, with 82% of patients 
having stage III or above disease.
An important observation from both PORTEC 3 and 
GOG 258 is that distant metastasis remains the primary 
mode of treatment failure for high-risk endometrial 
cancer patients. Also of note, patients treated with CT 
alone showed lower rates of distant failure at 5 years than 
patients treated with C-RT on GOG 258 (27% vs. 21%). 
Reasons for the increased rates of distant failure observed 
with combination therapy are uncertain, though possibili-
ties include: 1) planned treatment with 4 (CRT) versus 
6 (CT) cycles of carboplatin and paclitaxel is less effective 
at eradicating subclinical metastatic disease; 2) delay in 
initiation of systemic carboplatin paclitaxel due to admin-
istration of pelvic radiation on the CRT arm resulted in 
decreased treatment efficacy; or, 3) increased toxicity with 
combination cisplatin and radiation resulted in decreased 
bone marrow reserve and associated poor compliance with 
adjuvant carboplatin/paclitaxel. In support of this final 
possibility, approximately 75% of patients completed 4 or 
more cycles of carboplatin/paclitaxel chemotherapy in the 
CRT arms of GOG 258 and PORTEC 3, while 92% of 
patients completed 4 or more cycles of chemotherapy in 
the CT arm of GOG 258. In comparison, 93% of patients 
in our series completed 4 or more cycles of carboplatin and 
paclitaxel, and 84% completed all six planned cycles. The 
cumulative incidence of grade 3–5 hematologic toxicity 
in our study was 55%, which again compares favourably 
with the 52% rates observed on the CT arm of GOG 
258. In addition, we found that lack of completion of 
chemotherapy, and delays in chemotherapy significantly 
correlated with decreased rates of distant metastasis-free 
survival. A recently published SEER-Medicare database 
report of patients with advanced endometrial cancer found 
similarly that more cycles of chemotherapy administered 
correlated with increased overall survival [17]. These find-
ings suggest that CT-RT-CT, in comparison with other 
commonly used adjuvant regimens, may optimally impart 
Figure 2. Kaplan-Meier analysis for overall survival stratified by 
the completion of all planned cycles of chemotherapy versus 
early termination of chemotherapy (p = 0.01)
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local and distant disease control by allowing greater rates 
of completion of planned chemotherapy regimens among 
patients who receive radiation.
In summation, results of our study and others in 
which adjuvant sandwich therapy was used to reveal fa-
vourable disease-specific outcomes, including low rates 
of locoregional and distant recurrence. In addition, our 
results demonstrate that this regimen is associated with 
acceptable toxicity and high rates of compliance with 
planned chemotherapies. This is especially important as 
the completion of planned chemotherapy was a predic-
tor for improved overall survival and given that distant 
failure is the primary failure pattern amongst high-risk 
endometrial cancer patients. Though our relatively 
small patient numbers do not allow us to draw defini-
tive conclusions, our findings support further evaluation 
of sandwich therapy in future clinical trials evaluating 
combination therapy regimens in high-risk endometrial 
cancer patients. 
Conclusions
Our results are consistent with literature suggesting 
that the adjuvant therapy regimen of chemotherapy 
followed by radiation therapy followed by additional 
chemotherapy for high-risk endometrial cancer leads to 
acceptable toxicity and does not impede patients’ ability 
to complete chemotherapy. Randomized prospective 
studies are needed to compare the efficacy of this regi-
men with other commonly used regimens.
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